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We rationalized that derivatives of hydroxylamine may be non-toxic while retaining the ability to cleave thioester linkage. We first screened a panel of 12 hydroxylamine derivatives and identified NtBuHA, which was non-toxic, cleaved thioester linkage in palmitoylated proteins, mediated depletion of lysosomal ceroid deposits and suppressed apoptosis in both cultured cells from INCL patients and in the brains of Ppt1 −/− mice, which recapitulate virtually all clinical and pathological features of INCL. Moreover, we found that NtBuHA was neuroprotective and modestly, albeit substantially, extended lifespan in these mice without elevating methemoglobin levels. Our findings provide a proof of principle that non-toxic nucleophilic small molecules with antioxidant property, such as NtBuHA, are potential drug-targets for diseases caused by thioesterase deficiency, such as INCL.
RESULTS

Screening of hydroxylamine derivatives that mimic thioesterases
Thioester linkage in palmitoyl~CoA, as well as in palmitoylated proteins (constituents of ceroid) 18 , is cleaved by hydroxylamine with high specificity 14, 15, 22 . To determine whether hydroxylamine derivatives retain this property, we first screened a panel of 12 hydroxylamine derivatives ( Supplementary Table 1 ) for their ability to cleave thioester linkage in [ 14 C]palmitoyl~CoA. We used [ 14 C]palmitoyl~CoA because it is a model substrate of thioesterases including PPT1 and mediates the release of free [ 14 C]palmitic acid ( Fig. 1a) . As a positive control, we used the parent compound, hydroxylamine. We found that, like hydroxylamine, both water-soluble ( Fig. 1b) and DMSOsoluble ( Fig. 1c) hydroxylamine derivatives cleaved thioester linkage in [ 14 C]palmitoyl~CoA, releasing free [ 14 C]palmitate, albeit at varying degrees of efficiency. The densitometric quantitation of the released free [ 14 C]palmitate bands in thin-layer chromatography (TLC) (Fig. 1b,c) confirmed these results.
To determine whether the hydroxylamine derivatives are nontoxic, we treated cultured fibroblasts from INCL patients with each of the 10 of 12 derivatives and evaluated their viability. We excluded N,N-dibenzylhydroxylamine and N-tert-butyl-O- [1-[4-(chloromethyl) phenyl]ethyl]-N-(2-methyl-1-phenylpropyl) hydroxylamine, as these derivatives were insoluble in tissue culture medium. We found that all of the tested compounds, except for N-benzoyl-N-phenyl hydroxylamine, were non-toxic at concentrations up to 1 mM ( Supplementary Fig. 2) .
NtBuHA is non-toxic to cultured cells from INCL patients
To evaluate whether NtBuHA is non-toxic, we cultured lymphoblasts from INCL patients in the absence and presence of varying concentrations of NtBuHA (0-5 mM) and determined the viability of the cells by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method 23 . It should be noted that, although 1 mM NtBuHA was non-toxic to cultured INCL lymphoblasts, the viability of the cells gradually declined at higher concentrations ( Fig. 1d) . However, when these cells were cultured in medium containing 500 µM NtBuHA for varying lengths of time (12-60 h), cell viability was not altered (Supplementary Fig. 3a) .
To further confirm these results, we tested the plating efficiency of the cells after treatment with NtBuHA at varying concentrations ranging from 0.1 to 2.5 mM. We found that the plating efficiency of the cells remained unaffected after treatment with NtBuHA at concentrations of up to 1 mM, and the plating efficiency slightly declined when the NtBuHA concentration was raised to 2.5 mM ( Fig. 1e and  Supplementary Fig. 3b ). Taken together, these results indicate that NtBuHA is non-toxic to cultured cells from INCL patients at a wide range of concentrations.
NtBuHA cleaves thioester linkage in [ 14 C] palmitoyl~CoA We chose to study NtBuHA in further detail because a previous report indicated that this compound manifested potent mitochondrial antioxidant activity and prolonged longevity in normal mice and rats 24 . These properties of NtBuHA are especially relevant because high levels of endoplasmic reticulum (ER) and oxidative stress have been reported to cause apoptosis in cultured cells from INCL patients, as well as in the neurons of Ppt1 −/− mice 25 , contributing to neurodegeneration [26] [27] [28] and shortened lifespan 25 . Consistent with these findings, high levels of apoptosis have been reported in brain tissues of INCL patients 29 . Thus, we sought to determine whether NtBuHA-mediated cleavage of thioester linkage is dose and time dependent. We incubated 0.1 µCi of [ 14 C]palmitoyl~CoA with varying concentrations of NtBuHA (0-500 µM) and measured the levels of free [ 14 C]palmitate. NtBuHA efficiently cleaved thioester linkage and released free [ 14 C]palmitate in a dose-dependent manner (Supplementary Fig. 4a ).
We then incubated 0. Fig. 4b ). Taken together, these results suggest that NtBuHA efficiently cleaves thioester linkage in a dose-and timedependent manner.
NtBuHA cleaves thioester linkage in palmitoylated proteins
To determine whether NtBuHA cleaves thioester linkage in palmitoylated proteins, we used cultured lymphoblasts from INCL patients labeled with [ 35 S]cysteine, as previously reported 18 . We found that, compared with the cells grown in medium without NtBuHA, cells grown in NtBuHA-containing medium for 24 and 48 h yielded appreciably less intense [ 35 S]cysteine-labeled lipid thioester bands ( Fig. 1f and Supplementary Fig. 5a ). To confirm these results, we performed identical experiments using cultured lymphoblasts from nine different INCL patients who carried varying inactivating mutations in the PPT1 gene ( Supplementary Table 2 ). Compared with the density of the [ 35 S]cysteine-labeled lipid thioester bands from untreated INCL cells, those of the NtBuHA-treated counterparts yielded substantially less dense bands ( Fig. 1g and Supplementary Fig. 5b ).
The loss of intensity of [ 35 S]cysteine-labeled lipid thioester bands in NtBuHA-treated cells also indicates that NtBuHA cleaved the thioester linkage in S-acylated proteins, much like its parent compound, hydroxylamine. As expected, the normal control cells (n = 4) exhibited extremely low levels of [ 35 S]cysteine-labeled lipid thioester accumulation, unlike the more dense bands characteristically found in INCL cells ( Fig. 1g) . Collectively, these results indicate that NtBuHA cleaves thioester linkage in palmitoylated proteins in cultured cells from INCL patients in a dose-and time-dependent manner and mediates depletion of lipid thioesters in these cells.
NtBuHA depletes granular osmiophilic deposits in INCL cells
A physical correlate of ceroid deposition in the cells of INCL patients is the presence of granular osmiophilic deposits (GRODs) 13 . We sought to determine whether NtBuHA mediates the depletion of GRODs in INCL cells, which are detectable by transmission electron microscopy (TEM). Accordingly, we analyzed the levels of GRODs by TEM of cultured INCL lymphoblasts that were either untreated or treated with NtBuHA for 3 weeks before TEM analysis was performed. We found that, compared with the untreated controls, NtBuHA-treated cells contained either no GRODs or a substantially reduced number of GRODs ( Fig. 2a) . Quantitative analysis confirmed a significantly 1 6 1 0 VOLUME 16 | NUMBER 11 | NOVEMBER 2013 nature neurOSCIenCe a r t I C l e S decreased (t 77 = 7.61, P < 0.001, permutation t test) number of GRODs in NtBuHA-treated cells (Fig. 2b) . The morphometric analysis of the GRODs revealed that the size of the GRODs, when present in NtBuHAtreated cells, was also significantly smaller (t 66 = 4.68, P < 0.001 permutation t test) than those of the untreated cells ( Fig. 2c) .
We also conducted similar experiments using cultured fibroblasts from INCL patients. We found that, compared with the untreated INCL fibroblasts, which contained numerous highly dense GRODs (Supplementary Fig. 6a ), the NtBuHA-treated cells contained a markedly lower number of GRODs (Supplementary Fig. 6b,c) . These results indicate that NtBuHA is effective at mediating the depletion of GRODs in both cultured lymphoblasts and fibroblasts from INCL patients.
Normal serum methemoglobin in NtBuHA-treated Ppt1 −/− mice Given that hydroxylamine stimulates methemoglobin production, we sought to determine whether the hydroxylamine derivative (NtBuHA) elevated serum methemoglobin levels in mice. Accordingly, Figure 1 Hydroxylamine derivatives cleave thioester linkage in [ 14 , which in addition to N1-N3, showed virtually no high-density thioester bands. However, lymphoblasts from nine INCL patients ( Supplementary Table 2 ) clearly showed identifiable lipid thioester bands. The [ 35 S]-labeled lipid thioesters were resolved by TLC as previously reported 18 . + and − indicate NtBuHA treatment or untreated, respectively. Note the reduction in density of the radioactive lipid thioester bands in NtBuHA-treated samples. Box-whisker plots represent the first three quartiles (25%, median and 75%) and values 1.5× the interquartile range below the first quartile (lower horizontal line) and above the third quartile (upper horizontal line). NtBuHA
INCL patients npg a r t I C l e S we measured the blood methemoglobin levels in wild-type, untreatedand NtBuHA-treated Ppt1 −/− mice. We found that treatment of Ppt1 −/− mice with NtBuHA for up to 3 months did not lead to elevation of the methemoglobin levels ( Table 1) . We conclude that this derivative of hydroxylamine, at the dosages used in our experiments, is unlikely to have toxicity from the standpoint of increased methemoglobin levels. We next sought to determine whether NtBuHA crosses the bloodbrain barrier. Accordingly, we provided wild-type and Ppt1 −/− mice with NtBuHA in their drinking water and determined the levels of NtBuHA in perfused brain tissues by multiple reaction-monitoring mass spectrometry, as previously reported 30 . We found that NtBuHA, administered to 3-and 6-month-old Ppt1 −/− and wild-type mice, was readily detectable in the brain ( Table 2 ). These results suggest that orally administered NtBuHA is readily absorbed from the gastrointestinal tract and crosses the blood-brain barrier.
NtBuHA treatment depletes GRODs in Ppt1 −/− mouse brain
To determine whether the beneficial effects of NtBuHA observed in cellulo are reproducible in vivo, we treated 3-month-old Ppt1 −/− mice (n = 6) with NtBuHA continuously for 3 months. We tested these mice at 6 months of age, as this is the age at which they begin to manifest signs of neurological impairment and characteristic pathological features of INCL [26] [27] [28] 31 . Untreated age-and sex-matched Ppt1 −/− mice (n = 6) served as controls. At the end of the treatment period, the mice were killed and the cortical tissues were examined by TEM. We found that, although we detected no GRODs in the wild-type mice, high levels of GRODs were readily detectable in the cortical tissues of untreated Ppt1 −/− mice ( Fig. 2d) . Notably, the NtBuHAtreated Ppt1 −/− mice showed a markedly reduced number of GRODs ( Fig. 2d) . Quantitation of the GRODs in the brain cells of untreated and NtBuHA-treated Ppt1 −/− mice showed a significant reduction (t 16 = 2.89, P = 0.012, permutation t test) in the number of the GRODs (Fig. 2e) . These results indicate that NtBuHA-treatment mediates depletion of GRODs in the brains of Ppt1 −/− mice.
NtBuHA reduces autofluorescence in Ppt1 −/− mouse brain Accumulation of intracellular autofluorescent lipopigment material in the brain and in other tissues is a characteristic pathological finding in NCLs, including INCL 13 , and Ppt1 −/− mice 25, 26 . Accordingly, we analyzed Note that GRODS were completely depleted in most NtBuHA-treated cells (NtBuHA (1)), but a few cells contained GRODs (2) . Scale bar represents 500 nm. (b) Box plot analysis of GRODs counted from the TEM in untreated (n = 23) and NtBuHA-treated (n = 56) cells (t 77 = 7.61, P < 0.001, permutation t test). (c) Morphometric analysis of the GRODs in untreated (n = 47) and NtBuHA-treated (n = 21) cells (t 66 = 4.68, P < 0.001, permutation t test). (d) Electron micrographs of cerebral cortices of 6-month-old wild-type mice (WT, left) and untreated (middle) and NtBuHA-treated Ppt1 −/− mice (right). We found no GRODs in wild-type mouse cortices, whereas those of the untreated Ppt1 −/− mice showed a very high level of GRODs. Cortices from NtBuHA-treated mice showed a significantly reduced number of GRODs compared with those of untreated mice (t 16 = 2.89, P = 0.012, permutation t test). Scale bar represents 2 µm. (e) Quantitation of GRODs per cell in the brain sections from wild-type mice and untreated and NtBuHAtreated Ppt1 −/− mice. Representative electron micrographs from 3-6 mice from each group were analyzed. (f) Autofluorescence visualized by dark field microscopic analysis of cortical tissue sections of 6-month-old wild-type mice (left) and untreated (middle) and NtBuHA-treated (right) Ppt1 −/− mice. Densitometric analyses of autofluorescence in the brain tissues of untreated and NtBuHA-treated Ppt1 −/− mice (g) revealed a significant decline in autofluorescence in treated mice (t 28 = 11.78, P < 0.001, permutation t test). Scale bar represents 50 µm. Box-whisker plots represent the first three quartiles (25%, median and 75%) and values 1.5× the interquartile range below the first quartile (lower horizontal line) and above the third quartile (upper horizontal line). 
NtBuHA-treated Ppt1
-/-f g npg a r t I C l e S the brain tissues of NtBuHA-treated Ppt1 −/− mice for autofluorescence and compared them with untreated Ppt1 −/− and wild-type mice. We found that, although the brain tissues from wild-type mice had no autofluorescence, those of the untreated Ppt1 −/− mice manifested intense autofluorescence ( Fig. 2f) . Notably, NtBuHA-treated Ppt1 −/− mice showed significantly reduced (t 28 = 11.78, P < 0.001, permutation t test) autofluorescence ( Fig. 2f) . Quantitative analysis revealed that the intensity of autofluorescence in NtBuHA-treated Ppt1 -/mice was substantially lower (than that in untreated Ppt1 −/− mice ( Fig. 2g) .
Together, these results suggest that NtBuHA mediates the depletion of intracellular ceroid and decreases the number of GRODs per cell and the intensity of autofluorescence.
NtBuHA ameliorates ER and oxidative stress
Previously, we reported that ER and oxidative stress contribute to neuropathology in INCL [26] [27] [28] . Thus, we sought to determine whether NtBuHA treatment of Ppt1 −/− mice ameliorates these stresses. We performed western blot analysis of proteins in brain lysates from untreated and NtBuHA-treated Ppt1 −/− mice and determined the levels of the ER stress markers Grp-78, Grp-94 and ATF6. We found the levels of all three of the ER stress markers were markedly reduced in the brain tissues of NtBuHA-treated Ppt1 −/− mice compared with untreated mice (Supplementary Fig. 7) .
We then performed western blot analysis of brain lysates from NtBuHA-treated and untreated Ppt1 −/− mice to determine the levels of the oxidative stress markers superoxide dismutase-2 (SOD2) and catalase. The levels of these two enzymes increase in response to elevated oxidative stress to maintain cellular homeostasis, and a decrease in the levels of SOD2 and catalase can occur if a treatment is effective at reducing oxidative stress. We found that NtBuHA treatment substantially reduced the levels of both SOD2 and catalase (Supplementary Fig. 7) . Taken together, these results indicate that NtBuHA treatment is effective at reducing both ER and oxidative stress in the brains of Ppt1 −/− mice.
NtBuHA suppresses apoptosis in cultured INCL cells
Next, we sought to determine whether NtBuHA treatment protects cultured INCL lymphoblasts from apoptosis, which has been reported to be one of the major contributors of neuronal death in INCL patients 29 . Because PPT1 is ubiquitously expressed in all mammalian tissues and organs 32, 33 , we used cultured cells from INCL patients in our in vitro experiments. Moreover, these cultured cells manifest pathological changes (that is, accumulation of GRODs and increased apoptosis) that are virtually identical to those found in postmortem brain tissues from INCL patients [26] [27] [28] . Accordingly, we pretreated cultured lymphoblasts from INCL patients with 1 mM NtBuHA for 12 h and then treated them with H 2 O 2 (500 µM) in the presence or absence of NtBuHA (1 mM) for 3 h. As a control, we treated INCL lymphoblasts without NtBuHA pretreatment with the same concentration of hydrogen peroxide for 3 h.
Apoptosis was detected by annexin V staining and quantified by fluorescence-activated cell sorting (FACS) analysis. We found that H 2 O 2 treatment elevated the levels of apoptosis in cells that were not pretreated with NtBuHA (Fig. 3a,b) . However, in NtBuHApretreated lymphoblasts, H 2 O 2 failed to induce apoptosis above the basal level (Fig. 3a,b) . Similarly, cells that were first pretreated with NtBuHA and then incubated with H 2 O 2 in presence of NtBuHA (co-treated) also showed no alteration in apoptosis above the basal level in these cells (Fig. 3a,b) . Together, these results suggest that NtBuHA protects cultured INCL lymphoblasts from oxidative stressmediated apoptosis.
Reduced apoptosis in NtBuHA-treated Ppt1 −/− mouse brain To determine whether NtBuHA treatment protects against neuronal apoptosis in vivo, we performed TUNEL assay using cortical tissue sections from 6-month-old wild-type mice and untreated and NtBuHA-treated Ppt1 −/− mice. Although we found virtually no TUNEL-positive apoptotic cells in the brains of wild-type mice (Fig. 4a) , there were numerous apoptotic cells in the brains of the untreated Ppt1 −/− mice (Fig. 4b) . In contrast, the brain tissues of npg a r t I C l e S the NtBuHA-treated Ppt1 −/− mice showed significantly lower levels (t 19 = 15.74, P < 0.001, permutation t test) of TUNEL-positive cells (Fig. 4c,d) .
To further confirm these results, we performed western blot analysis of brain tissue lysates for two biochemical correlates of the oxidative stress-mediated mitochondrial pathway of apoptosis: cleaved caspase-9 and cleaved PARP-1. Compared with the brain tissues of wild-type mice, those of untreated Ppt1 −/− mice showed significantly higher levels of both cleaved caspase-9 and cleaved PARP-1 ( Fig. 4e-g) . This suggests that NtBuHA protects brain neurons from apoptosis in an INCL mouse model.
NtBuHA retards progression of brain atrophy in Ppt1 −/− mice Elevated levels of apoptosis in the brain of Ppt1 −/− mice [26] [27] [28] and in INCL patients 29 are suggested to cause brain atrophy. Thus, we determined the brain size and weight of untreated and NtBuHA-treated Ppt1 −/− mice and wild-type mice. We found that the size and weight of the brains of untreated Ppt1 −/− mice were markedly decreased compared with those of wild-type mice (Fig. 5a,b) . In contrast, both of these parameters were markedly higher in NtBuHA-treated Ppt1 −/− mice compared with those of the untreated Ppt1 −/− mice (Fig. 5a,b) .
To determine whether the brain size and weight correlated with neuron density, we performed immunohistochemical analyses of cortical tissue sections from wild-type mice and untreated and NtBuHAtreated Ppt1 −/− mice using antibody to NeuN, a neuronal marker protein. Compared with the brains of wild-type mice, those of the untreated Ppt1 −/− mice had a significantly reduced number (t 8 = 21.8, P = 0.008, permutation t test) of NeuN-positive cells (Fig. 5c,d) .
In contrast, the brains of NtBuHA-treated Ppt1 −/− mice showed a modestly, but significantly, higher (t 9 = 8.17, P = 0.002, permutation t test) number of NeuN-positive cells than those of untreated Ppt1 −/− mice (Fig. 5c,d) .
To evaluate the degree of protection provided by NtBuHA in neurons from various cortical layers, we immunostained brain sections from wild-type mice and untreated and NtBuHA-treated Ppt1 −/− mice using antibodies to Cux1 (cortical layers II-IV) and Ctip2 (cortical layers IV-VI). We then quantitated the Cux1-and Ctip2positive neurons in these sections. Compared with wild-type mice, the numbers of Cux1- (Supplementary Fig. 8a-c) and Ctip2-positive ( Supplementary Fig. 8a,b,d) neurons in the brains of Ppt1 −/− mice were reduced to 53% and 35%, respectively. In contrast, the brains of the NtBuHA-treated Ppt1 −/− mice showed a markedly increased number of both Cux1-and Ctip2-positive neurons in the mediolateral secondary visual cortex compared with those of the untreated Ppt1 −/− mice (Supplementary Fig. 8) . Given that one of the prominent neuropathological features of INCL is cortical atrophy, we also measured the cortical thickness in the mediolateral secondary visual cortex region (Supplementary Fig. 9a ) of cresyl violet-stained brain sections from wild-type, untreated Ppt1 −/− and NtBuHA-treated Ppt1 −/− mice (Supplementary Fig. 9b) . Quantitative analysis revealed a marked decline in cortical thickness in untreated Ppt1 −/− mice compared with wild-type mice, whereas this decline was less pronounced in the NtBuHA-treated Ppt1 −/− mice (Supplementary Fig. 9c ). Cumulatively, these results provide supporting evidence that NtBuHA treatment has neuroprotective effects in the brains of Ppt1 −/− mice.
Next, we sought to determine whether NtBuHA treatment of Ppt1 −/− mice manifests any beneficial effect on astroglial activation, as assessed by higher levels of expression of glial fibrillary acidic protein (GFAP). Previous studies have found that increased GFAP expression precedes neuronal death in these mice 34 . We first performed western blot analysis of cortical lysates from wild-type mice and those of the untreated-and NtBuHA-treated Ppt1 −/− mice using GFAP and NeuN antibodies, respectively. We found markedly higher levels of GFAP expression in the brain tissue lysates of the untreated Ppt1 −/− mice compared with those of wild-type mice (Fig. 5e,f) . However, the levels of NeuN were inversely proportional to those of the GFAP (Fig. 5e,g) . Immunohistochemical analysis of cortical tissues corroborated the results of the western blot analyses (Fig. 5h,i) . Compared with the untreated Ppt1 −/− mice, the NtBuHA-treated Ppt1 −/− mice showed significantly decreased GFAP levels (t 6 = 5.19, P = 0.03, permutation t test), whereas NeuN levels were moderately elevated ( Fig. 5e-i) . These findings indicate that NtBuHA has beneficial effects in reducing the activation of astroglia and may be involved in preventing neurodegeneration in this mouse model of INCL. 
NtBuHAtreated Ppt1
-/- Figure 4 NtBuHA suppresses apoptosis in Ppt1 −/− mouse brain. (a-c) Apoptotic cells were detected by TUNEL assay in brain sections from 6-month-old wild-type mice (n = 9, a) and untreated (n = 9, b) and NtBuHA-treated Ppt1 −/− mice (n = 12, c). TUNEL-positive apoptotic cells are reddish brown. (d) Graphic representation of the levels of apoptotic cells in the brain of wild-type mice and untreated and NtBuHA-treated Ppt1 −/− mice (wild type versus untreated: t 16 = 27.63, P < 0.001, permutation t test; (untreated versus NtBuHA treated: t 19 = 15.74, P < 0.001, permutation t test). (e) Western blot analysis of cortical tissue homogenates prepared from 6-month-old wild-type mice and untreated and NtBuHA-treated Ppt1 −/− mice for cleaved caspase-9 and cleaved PARP-1. Full-length blots of the cropped gel images are provided in Supplementary Figure 10a. (f,g) Densitometric quantitation of cleaved caspase-9 (f) and cleaved PARP-1 (g) from three independent experiments (f: wild type versus untreated, t 10 = 11.65, P = 0.002, permutation t test; untreated versus NtBuHA treated, t 10 = 8.23, P = 0.002, permutation t test; g: wild-type versus untreated, t 9 = 5.08, P = 0.004, permutation t test; untreated versus NtBuHA treated, t 10 = 4.73, P = 0.015, permutation t test). Box-whisker plots represent the first three quartiles (25%, median and 75%) and values 1.5× the interquartile range below the first quartile (lower horizontal line) and above the third quartile (upper horizontal line). npg a r t I C l e S NtBuHA preserves motor function and extends lifespan Impaired motor coordination is one of the first signs of neurological deterioration in INCL patients 13 . Given that NtBuHA functionally mimics PPT1, we tested wild-type mice and untreated and NtBuHAtreated Ppt1 −/− mice at 6 and 8 months of age for motor coordination using the rotarod performance test 35 . We first performed the rotarod test using 3-month-old wild-type and Ppt1 −/− mice because they do not manifest signs of motor deficit at this age. As expected, there were virtually no differences in performance between the wildtype and Ppt1 −/− mice at all three speeds (4, 8 and 12 r.p.m. for 60 s; Supplementary Fig. 9d) . We then performed the same test using 6-month-old wild-type, untreated Ppt1 −/− and NtBuHA-treated Ppt1 −/− mice. Untreated 6-month-old Ppt1 −/− mice manifested a clear motor deficit, whereas NtBuHA-treated mice had near-normal motor coordination (Fig. 6a-c and Supplementary Video 1) . The rotarod test on 8-month-old wild-type mice and untreated and NtBuHA-treated Ppt1 −/− mice yielded similar results (Fig. 6d) .
To determine whether NtBuHA-treatment of the Ppt1 −/− mice improves their endurance, we repeated the rotarod test at the highest speed (12 r.p.m.) for 300 s instead of 60 s using wild-type mice and untreated and NtBuHA-treated Ppt1 −/− mice. The endurance time of the wild-type mice was markedly higher than that of the untreated Ppt1 −/− mice (wild type, 224 ± 84 s; untreated Ppt1 −/− , 12 ± 6 s; Supplementary  Fig. 9e) . In contrast, the endurance time of the NtBuHA-treated Ppt1 −/− mice was modestly longer than that of the untreated Ppt1 −/− mice (untreated Ppt1 −/− , 12 ± 6 s; NtBuHA-treated Ppt1 −/− , 53 ± 24 s).
We also tested the Ppt1 −/− mice for their exploratory behavior using the open field test 36 . Compared with 6-and 8-month-old untreated Ppt1 −/− mice, those treated with NtBuHA showed improved exploratory behavior (Fig. 6e,f) . Taken together, these results suggest that NtBuHA treatment of Ppt1 −/− mice not only cleaves thioester linkage in palmitoylated proteins, mediates depletion of ceroid, reduces ER and oxidative stress, and suppresses neuronal apoptosis, but also considerably slows the deterioration of motor coordination and exploratory behavior.
To determine whether the observed beneficial effects of NtBuHA treatment extended the lifespan of the mice, we divided 190 3-monthold Ppt1 −/− mice into two groups: one group (n = 110) received no treatment (control) and the other group (n = 80) was treated with NtBuHA. The status of all mice was monitored on a daily basis and the mice were killed when they could not reach for food and water. The lifespan of NtBuHA-treated mice was extended compared with that of the untreated mice (Fig. 6g) . The quantitative analysis confirmed Figure 5 The effects of NtBuHA on brain size, weight, neuron density, GFAP and NeuN expression. (a) Representative brain size of wild-type (left), untreated Ppt1 −/− (middle) and NtBuHA-treated Ppt1 −/− mice (right). (b) The brain weights of wild-type (n = 12), untreated Ppt1 −/− (n = 5) and NtBuHA-treated Ppt1 −/− (n = 12) mice were determined (wild type versus untreated, t 15 = 13.3, P < 0.001, permutation t test; untreated versus NtBuHA treated, t 15 = 5.1, P < 0.001, permutation t test). (c) The neuron densities in the cerebral cortex of representative wildtype (left), untreated Ppt1 −/− (middle) and NtBuHA-treated Ppt1 −/− (right) mice were determined after staining the cortical tissue sections using antibodies to NeuN. Sections from at least four mice in each category (wild-type, untreated Ppt1 −/− and NtBuHAtreated Ppt1 −/− ) were analyzed. (d) Graphic representation of the levels of NeuN-positive neurons in wild-type, untreated Ppt1 −/− and NtBuHA-treated Ppt1 −/− mice (wild type versus untreated, t 8 = 21.8, P = 0.008, permutation t test; untreated versus NtBuHA treated, t 9 = 8.17, P = 0.002, permutation t test). (e-g) Western blot analysis (e) and densitometric quantitation (f,g) of brain lysates from wild-type, untreated Ppt1 −/− and NtBuHA-treated Ppt1 −/− mice for GFAP and NeuN (f: wild type versus untreated, t 10 = 49.7, P = 0.002, permutation t test; untreated versus NtBuHA treated, t 10 = 15.1, P = 0.002, permutation t test; g: wild type versus untreated, t 10 = 8.7, P = 0.002, permutation t test; untreated versus NtBuHA treated, t 10 = 8.76, P = 0.002, permutation t test). Full-length blots of the cropped gel images are presented in Supplementary  Figure 10b . (h,i) Immunohistochemistry of brain sections (h) showing GFAP-positive cells and quantitation (i) of GFAP-positive cells per mm 2 (wild type versus untreated, t 6 = 36.35, P = 0.03, permutation t test; untreated versus NtBuHA treated, t 6 = 5.19, P = 0.03, permutation t test). All of the mice used in these experiments were 6 months old. Box-whisker plots represent the first three quartiles (25%, median and 75%) and values 1.5× the interquartile range below the first quartile (lower horizontal line) and above the third quartile (upper horizontal line). These results strongly suggest that NtBuHA treatment of Ppt1 −/− mice not only slows down the progression of neuropathology, but also modestly extends their lifespan.
DISCUSSION
We found that thioesterase-mimetic, nucleophilic small molecules with antioxidant properties, such as NtBuHA, cleaved thioester linkage in palmitoylated proteins (constituents of ceroid) with high specificity. We also found that this small molecule was non-toxic, mediated depletion of ceroid deposits and suppressed apoptosis in cultured cells from INCL patients. Furthermore, results obtained in cellulo were reproduced in vivo when Ppt1 −/− mice were treated with NtBuHA. Notably, in Ppt1 −/− mice, orally administered NtBuHA crossed the blood-brain barrier, did not stimulate methemoglobin production, mediated ceroid depletion, suppressed neuronal apoptosis, slowed neurological deterioration and caused a modest, albeit significant, extension of lifespan.
In the CNS, a large number of protein functions require dynamic palmitoylation 16, 37 . Although post-translational lipid modifications of proteins, such as palmitoylation, are critical in many biological processes, removal of the lipid moieties (depalmitoylation) from these lipid-modified proteins is also important for their recycling or degradation in lysosomes. Thus, genetic deficiency of the lysosomal thioesterase PPT1 leads to a devastating neurodegenerative LSD, INCL. Because children afflicted with INCL are normal at birth and disease manifestation does not occur before 11-18 months of age, there is a window of opportunity to develop and implement therapeutic interventions that arrest disease pathology.
To date, INCL is the only well-characterized neurodegenerative LSD caused by the deficiency of PPT1. Mammalian thioesterases are both cytosolic (APT1 and APT2) 38, 39 and lysosomal (PPT1 and PPT2) 9,10 , which catalyze the cleavage of thioester linkage in S-acylated (S-palmitoylated) proteins. Hydroxylamine cleaves thioester linkage with high specificity 14, 15 , although it was not known whether its derivatives can cleave thioester linkage. We found that its derivatives, including NtBuHA, also cleave this linkage in S-acylated proteins and mediate ceroid depletion. However, although NtBuHA depalmitoylates S-acylated proteins, it is unlikely that it would be effective at depalmitoylating proteins in which the palmitate is linked to cysteine residues via amide linkage (N-palmitoylation).
In addition to its role in enhancing membrane affinity, palmitoylation promotes protein-protein interactions 14, 15 . A recent report suggested that palmitoylation-induced aggregation of mutant cysteine-string protein-α (CSPα), and possibly other proteins that undergo palmitoylation, may underlie adult-onset NCL 40 . Thus, thioesterase-mimetic small molecules such as NtBuHA may ameliorate the pathogenesis of diseases caused not only by thioesterase wild type versus untreated, t 8 = 8.6, P = 0.005, permutation t test; untreated versus NtBuHA treated, t 13 = 3.2, P = 0.01, permutation t test; 8 month: wild type versus untreated, t 10 = 37.0, P = 0.002, permutation t test; untreated versus NtBuHA treated, t 11 = 10.9, P = 0.001, permutation t test). (g) Survival plots (Kaplan-Meyer analysis) of untreated and NtBuHA-treated Ppt1 −/− mice. Untreated (n = 110) and NtBuHA-treated Ppt1 −/− (n = 80) mice were killed when they could not reach for food or water (median survival: 242 d for untreated, 277 d for treated, χ 2 (161, df = 1), P < 0.001). Box-whisker plots represent the first three quartiles (25%, median and 75%) and values 1.5× the interquartile range below the first quartile (lower horizontal line) and above the third quartile (upper horizontal line).
a r t I C l e S deficiency, but also those caused by the accumulation of aggregateprone palmitoylated proteins. We previously reported that high levels of ER and oxidative stress lead to neuronal apoptosis in INCL cells and in Ppt1 −/− mice [26] [27] [28] . It has been reported that NtBuHA has a potent antioxidant property 24 . We found that NtBuHA not only mediates depletion of intracellular ceroid, but also protects PPT1-deficient cells from oxidative stressmediated apoptosis as a result of its anti-oxidant property. This may suggest that the neuroprotective effects of NtBuHA may stem not only from its ability to cleave thioester linkage in S-acylated proteins, but also from its anti-oxidant property. Given that NtBuHA functionally mimics all thioesterases, we propose that nucleophilic small molecules with antioxidant properties similar to that of NtBuHA may have therapeutic potential not only for INCL resulting from PPT1 deficiency, but also for as yet unrecognized diseases resulting from deficiencies of other thioesterases.
Although several therapeutic approaches are currently being used for the LSDs with systemic (visceral) involvement 41 , the development of effective treatment strategies for LSDs affecting the CNS remains challenging 42 . For INCL, several approaches are currently being used to develop an effective treatment strategy for this uniformly fatal disease [43] [44] [45] [46] [47] [48] . However, delivering macromolecules to the brain as therapeutics for neurodegenerative diseases remains challenging. Consequently, most of the potential therapies face this challenge, although new strategies to overcome the obstacles are being tested 49 . We used a mechanistic approach to identify non-toxic, small molecules with antioxidant and thioesterase-mimetic properties that readily cross the blood-brain barrier. Our results indicate that NtBuHA fulfills at least some of the criteria required to be considered a potential drug target for INCL.
Despite the positive beneficial effects of NtBuHA, Ppt1 −/− mice ultimately succumbed to INCL. Although we do not have a clear understanding of the mechanism of death of the NtBuHA-treated mice, there are several possibilities that may account for this outcome. One of these possibilities is that the time of initiation of NtBuHA treatment may be critical. The other possibility is that our NtBuHA dosage may not have been adequate to maintain the full therapeutic level in the brain. To the best of our knowledge, no off-target adverse effects of NtBuHA have been reported, but, although we uncovered no adverse effects of this small molecule, we are nonetheless mindful that, as with most drugs, NtBuHA may also have such adverse effects. Nevertheless, our findings provide a proof of concept that thioesterase-mimetic small molecules with antioxidant properties, such as NtBuHA, may offer a mechanism-based potential therapeutic option not only for INCL, but also for as yet unrecognized diseases that are caused by the deficiency of either cytosolic or lysosomal thioesterases.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
